April 13, 2018
Announcement no. 8
BioPorto A/S held its Annual General Meeting today where the shareholders approved the report on the Company’s activities and adopted the 2017 Annual Report. In addition, the general meeting adopted the proposed profit/loss allocation and granted discharge to the Board of Directors and the Executive Management. Finally, the remuneration for the Board of Directors was approved.
Thomas Magnussen, Torben A. Nielsen and Kirsten Aarup Drejer were re-elected as members of the Board of Directors. In addition, Britt Meelby Jensen was elected as a new board member. Immediately following the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its Chairman and Torben A. Nielsen as its Vice Chairman.
The proposal from the Board of Directors regarding a renewal of the authorisation to issue warrants under item 6 of the agenda was adopted.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.
Hellerup, April 13, 2018
BioPorto A/S
The Board of Directors
For further information, please contact:
Peter M. Eriksen, CEO
Gry Husby Larsen, Investor Relations
Telephone +45 4529 0000, e-mail investor@bioporto.com
The kidney biomarker NGAL
Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million dies. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ Copenhagen stock exchange.
Attachment
